Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicentre, Phase II Study to Evaluate the Safety and Efficacy of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

NCT05009953 is registered in ClinicalTrials.gov with CSPC Ouyi Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05009953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05009953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicentre, Phase II Study to Evaluate the Safety and Efficacy of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
Lead sponsor
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
September 1, 2021
Completion date
January 16, 2023
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced biliary tract cancer, extrahepatic cholangiocarcinoma, gallbladder carcinoma, intrahepatic cholangiocarcinoma